Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PELOTON THERAPEUTICS, INC.

(PLTX)
SummaryNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Peloton Therapeutics To Seek Acquisitions

04/26/2019 | 12:00am EST

Peloton Therapeutics, Inc. will look for acquisitions. Peloton Therapeutics is offering $115,000,000 Common Stock, $0.0001 par value per share. As of the date of this prospectus, it cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that it will actually spend on the uses. It believes opportunities may exist from time to time to expand current business through license or acquisitions of, or investments in, complementary businesses, products or technologies. While it has no current agreements, commitments or understandings for any specific licenses, acquisitions or investments at this time, we may use a portion of the net proceeds for these purposes.


ę S&P Capital IQ 2019
All news about PELOTON THERAPEUTICS, INC.
2019Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.
CI
2019Peloton Therapeutics Announces Board Changes
CI
2019Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.
CI
2019Peloton Therapeutics To Seek Acquisitions
CI
2019Peloton Therapeutics, Inc. announced that it has received $150 million in funding from ..
CI
2018Peloton Therapeutics Announces Appointment of John Moore as General Counsel and Corpora..
CI
2018Peloton Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer
CI
2018Peloton Therapeutics Initiates Phase 2 Trial of OralHIF-2a Inhibitor PT2977 for Treatme..
CI
2018Peloton Therapeutics, Inc. Announces Board Changes
CI
2017Peloton Therapeutics, Inc. Announces Results from A Phase 1 Study Evaluating PT2385 in ..
CI
More news
Financials (USD)
Sales 2018 - - -
Net income 2018 -36,1 M - -
Net cash 2018 29,9 M - -
P/E ratio 2018 -
Yield 2018 -
Capitalization 711 M 711 M -
EV / Sales 2017 -
EV / Sales 2018 -
Nbr of Employees 64
Free-Float -
Income Statement Evolution
Managers and Directors
John A. Josey President, Chief Executive Officer & Director
Alan A. Musso Chief Financial Officer
David V. Goeddel Chairman
Brett A. Ringle Director
Helen Susan Kim Director
Sector and Competitors
1st jan.Capi. (M$)
PELOTON THERAPEUTICS, INC.0.00%711
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982